Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis

Background: There may be a temporal association between some antipsychotics and prolongation of the heart-rate-corrected QT interval (QTc) representin g a delay in ventricular repolarization. QTc prolongation significantly exc eeding normal intraindividual and interindividual variation may increase th e risk of ventricular tachydysrhythmias, especially torsade de pointes, and therefore, sudden cardiac death. Method: Electrocardiogram recordings obtained as part of the safety assessm ent of olanzapine in 4 controlled, randomized clinical trials (N = 2700) we re analyzed. These analyses were conducted to characterize any change in QT c temporally associated with olanzapine, compared with placebo, haloperidol , and risperidone, in acutely psychotic patients (DSM-III-R and DSM-IV) and to characterize variability and temporal course of the QTc in this patient population. Changes from baseline to minimum and maximum QTc were tested f or significance, and baseline to acute-phase endpoint change in mean QTc wa s tested for significance within treatments and for differences between ola nzapine and comparators. The possibility of a linear relationship between d ose of olanzapine and mean change in QTc, as well as incidence of treatment -emergent prolongation of QTc (change from < 430 msec at baseline to <great er than or equal to> 430 msec at endpoint), was tested. Results: The incidence of maximum QTc greater than or equal to 450 msec dur ing treatment was approximately equal to the incidence of QTc greater than or equal to 450 msec at baseline. Conclusion: Results of these analyses suggest that olanzapine, as therapeut ically administered to patients with schizophrenia and related psychoses, d oes not contribute to QTc prolongation resulting in potentially fatal ventr icular arrhythmias.